Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?
Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.
Lupin just cracked China with a flu drug. Why investors may want to look closer
Lupin’s China debut starts with flu medicine. The bigger story is whether one approval can open a larger paediatric pharma pathway.
Can Traws Pharma turn hantavirus urgency into a credible antiviral program?
Hantavirus has no specific antiviral option. Traws Pharma’s next test is turning outbreak urgency into credible clinical candidates.